rhCG

Phase 1Small molecule

UUniversity of Virginia

rhCG is one of 5 small molecule programs targeting Hyperandrogenism. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HyperandrogenismActive, not recruiting

HyperandrogenismPhase 1

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Hyperandrogenism

#DrugCompanyPhaseTrials

Lupron

AbbVie

Phase 2

1 2

Aldactone

Pfizer

Phase 1

1 3

Micronized Progesterone

AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Phase 1

1 4

Ethinyl Estradiol/norethindrone

AstraZeneca

Phase 2

1 5

rhCG

UUniversity of Virginia

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hyperandrogenism1 trial

Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS

Recruiting·UUniversity of Virginia·Phase 1·NCT03905603·144 enrolled

Effectiveness1 trial

Effectiveness and Safety Study of Fixed Versus Flexible of Gonadotropin-releasing Hormone Antagonist Protocol

Unknown status·CChong Qing Reproducive and Genetic Institute·N/A·NCT02635607·200 enrolled

Adolescent1 trial

Ovarian Contribution to Androgen Production in Adolescent Girls

Unknown status·UUniversity of Virginia·N/A·NCT01421810·80 enrolled

Ovulation Induction1 trial

Comparison Between Recombinant Versus Urinary hCG for Ovulation Induction in High Responders

Unknown status·EEugonia·Phase 4·NCT00415766·150 enrolled

Ovulation1 trial

HCG Levels After Ovulation Triggering as Predictors of ICSI Outcome

Completed·MMansoura University··NCT05969834·100 enrolled

1 more indication

Hydrocortisone1 trial

Effect of Longer-term Adrenal Suppression Using Low Dose Hydrocortisone on Androgen Overproduction

Withdrawn·UUniversity of Virginia·Phase 1·NCT01422733

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for rhCG. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — rhCG compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for rhCG. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Virginia company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: UUniversity of Virginia

rhCG

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hyperandrogenism1 trial

Effectiveness1 trial

Adolescent1 trial

Ovulation Induction1 trial

Ovulation1 trial

Hydrocortisone1 trial

References

Drug Info

Quick Facts

Related News